EA201071235A1 - Жидкая композиция для деферипрона с приятным вкусом - Google Patents

Жидкая композиция для деферипрона с приятным вкусом

Info

Publication number
EA201071235A1
EA201071235A1 EA201071235A EA201071235A EA201071235A1 EA 201071235 A1 EA201071235 A1 EA 201071235A1 EA 201071235 A EA201071235 A EA 201071235A EA 201071235 A EA201071235 A EA 201071235A EA 201071235 A1 EA201071235 A1 EA 201071235A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liquid composition
effective amount
taste
per liter
deferipronon
Prior art date
Application number
EA201071235A
Other languages
English (en)
Other versions
EA022751B1 (ru
Inventor
Майкл Спино
Анита Хой
Цыхуа Янг
Мохаммед Н. Кабир
Original Assignee
Апотекс Текнолоджиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апотекс Текнолоджиз Инк. filed Critical Апотекс Текнолоджиз Инк.
Publication of EA201071235A1 publication Critical patent/EA201071235A1/ru
Publication of EA022751B1 publication Critical patent/EA022751B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Пероральная фармацевтическая жидкая композиция, включающая деферипрон и композицию, маскирующую вкус, указанная композиция, маскирующая вкус, включает эффективное количество подсластителя (такого как сукралоза) на литр жидкой композиции, эффективное количество средства, способствующего загущению и суспендированию, (например, гидроксиэтилцеллюлоза) на литр жидкой композиции, эффективное количество увлажнителя (такого как глицерин) на литр жидкой композиции и эффективное количество по меньшей мере одного ароматического средства, где конечная форма указанного фармацевтического препарата с замаскированным вкусом имеет, в основном, негорький и приятный вкус.
EA201071235A 2008-04-25 2008-04-25 Жидкая композиция деферипрона с замаскированным вкусом EA022751B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2008/000784 WO2009129592A1 (en) 2008-04-25 2008-04-25 Liquid formulation for deferiprone with palatable taste

Publications (2)

Publication Number Publication Date
EA201071235A1 true EA201071235A1 (ru) 2011-06-30
EA022751B1 EA022751B1 (ru) 2016-02-29

Family

ID=41216357

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071235A EA022751B1 (ru) 2008-04-25 2008-04-25 Жидкая композиция деферипрона с замаскированным вкусом

Country Status (25)

Country Link
US (1) US8703156B2 (ru)
EP (1) EP2268282B1 (ru)
KR (1) KR101490721B1 (ru)
CN (1) CN102014904B (ru)
AP (1) AP2010005454A0 (ru)
AU (1) AU2008355464C1 (ru)
BR (1) BRPI0822206B8 (ru)
CA (1) CA2722393A1 (ru)
CR (1) CR11744A (ru)
CY (1) CY1116146T1 (ru)
DK (1) DK2268282T3 (ru)
EA (1) EA022751B1 (ru)
ES (1) ES2539414T3 (ru)
HK (1) HK1152871A1 (ru)
HR (1) HRP20150083T1 (ru)
IL (1) IL208876A (ru)
MX (1) MX2010011701A (ru)
NZ (1) NZ588602A (ru)
PL (1) PL2268282T3 (ru)
PT (1) PT2268282E (ru)
RS (1) RS53689B1 (ru)
SI (1) SI2268282T1 (ru)
UA (1) UA102254C2 (ru)
WO (1) WO2009129592A1 (ru)
ZA (1) ZA201008374B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
SG177462A1 (en) 2009-07-03 2012-02-28 Apotex Technologies Inc Fluorinated derivatives of 3-hydroxypyridin-4-ones
AU2013343250A1 (en) 2012-11-12 2015-04-09 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferipone
US20190240144A1 (en) * 2016-05-18 2019-08-08 Khashayar Karimian Effervescent deferiprone tablet
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
MA50201A (fr) 2017-10-25 2021-04-28 Chiesi Farm Spa Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
MX2021010945A (es) * 2019-03-14 2021-10-13 Neuroenergy Ventures Inc Formula que enmascara el sabor para compuestos de cuerpos cetonicos.
NL2024161B1 (en) * 2019-11-05 2021-07-20 Mperium B V Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
US20240091217A1 (en) 2022-07-29 2024-03-21 Sushma Paul BERLIA Stable pharmaceutical oral liquid formulation of an antispasmodic agent

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
NL300788A (ru) 1962-12-20
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308055D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
USRE34313E (en) 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8329043D0 (en) 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
EP0336369A1 (en) 1988-04-04 1989-10-11 E.R. Squibb & Sons, Inc. 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones
DE3826846A1 (de) 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
NO941358L (no) 1993-04-16 1994-10-17 Mcneil Ppc Inc Vandig farmasöytisk suspensjon og fremgangsmåte for fremstilling derav
CA2181463A1 (en) 1994-01-31 1995-08-03 Fu-Ning Fung Method of synthesizing gamma pyrones
JP2001508755A (ja) * 1994-04-08 2001-07-03 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳動物でラジカルダメージを減少させるために鉄キレート化合物を用いる方法
CA2172807C (en) 1994-08-01 1999-10-12 Keith S. Lienhop Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
KR100746753B1 (ko) 1998-08-28 2007-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
WO2002072102A1 (en) * 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
WO2003075910A1 (en) 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
MXPA04008720A (es) * 2002-03-12 2004-12-06 Squibb Bristol Myers Co Suspension oral de sabor agradable y metodo.
AU2003251920A1 (en) 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
DE10336497B4 (de) 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
CN1980574A (zh) * 2004-05-06 2007-06-13 锡德克斯公司 包含舍曲林和磺基烷基醚环糊精的掩味的制剂
JP2008500347A (ja) 2004-05-24 2008-01-10 ニュー・ヨーク・ユニヴァーシティー 高血糖症による血糖の急激な増加及び／又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070197469A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
MY151412A (en) 2006-02-22 2014-05-30 Munnich Arnold The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
PE20081596A1 (es) 2007-03-28 2009-02-05 Apotex Technologies Inc Derivados fluorinados de deferiprona
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds

Also Published As

Publication number Publication date
EP2268282A4 (en) 2011-06-22
NZ588602A (en) 2012-08-31
BRPI0822206B1 (pt) 2019-03-19
IL208876A (en) 2015-02-26
CN102014904A (zh) 2011-04-13
CN102014904B (zh) 2013-02-06
KR101490721B1 (ko) 2015-02-06
AP2010005454A0 (en) 2010-12-31
UA102254C2 (ru) 2013-06-25
EP2268282A1 (en) 2011-01-05
MX2010011701A (es) 2010-12-06
CA2722393A1 (en) 2009-10-29
CY1116146T1 (el) 2017-02-08
EA022751B1 (ru) 2016-02-29
ES2539414T3 (es) 2015-06-30
CR11744A (es) 2011-01-10
EP2268282B1 (en) 2014-10-29
KR20100135316A (ko) 2010-12-24
US20110039897A1 (en) 2011-02-17
HK1152871A1 (en) 2012-03-16
DK2268282T3 (en) 2014-11-24
BRPI0822206B8 (pt) 2021-05-25
AU2008355464A1 (en) 2009-10-29
RS53689B1 (en) 2015-04-30
ZA201008374B (en) 2012-01-25
BRPI0822206A2 (pt) 2015-06-23
US8703156B2 (en) 2014-04-22
WO2009129592A1 (en) 2009-10-29
IL208876A0 (en) 2011-01-31
PL2268282T3 (pl) 2015-04-30
PT2268282E (pt) 2015-02-05
SI2268282T1 (sl) 2015-01-30
AU2008355464B2 (en) 2014-04-10
AU2008355464C1 (en) 2014-11-20
HRP20150083T1 (hr) 2015-03-13

Similar Documents

Publication Publication Date Title
EA201071235A1 (ru) Жидкая композиция для деферипрона с приятным вкусом
MY146969A (en) Dpp iv inhibitor formulations
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
EA200970156A1 (ru) Пиридизиноновые производные
BRPI0915084B8 (pt) composto, e, composição farmacêutica
BRPI0507198A (pt) derivados de bisariluréia
NO20090175L (no) Stabile laquinimod sammensetninger
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
EA200801997A1 (ru) Новые соединения
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
CR10665A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
SG158091A1 (en) Imidazoazepinone compounds
BRPI0922870A8 (pt) uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
ITTO20120776A1 (it) Procedimento per mascherare l'amaro di un filtro uv
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title